Evaluate the utility of VEXUS score as a marker for acute kindey injury in patients of septic shock.

Not yet recruiting

• Conditions: Other acute kidney failure,

• Registration Number: CTRI/2025/03/083686
• Lead Sponsor: Max superspeciality hospital

Brief Summary

Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular and metabolic abnormalities are associated with greater risk of mortality. Venous congestion is a promising physiological marker that may be able to help direct resuscitation of patients with septic shock. Venous congestion is an important haemodynamic state in sepsis patients because it is associated with impaired organ function, particularly acute kidney injury. Therefore, we intend to evaluate of VEXUS score as a marker for acute kidney injury in patients of septic shock.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-03-24
• Study Start: 2025-04-15

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

Patients who fulfil the septic shock definition according to the Sepsis-3 consensus conference.

Exclusion Criteria

• Patient’s refusal to participate.
• Patients in which more than 4 hours have elapsed since diagnosis of septic shock.
• Anticipated to undergo immediate surgery.
• Hemodynamic instability due to active haemorrhage.
• Patients with previously known conditions that interfere with Doppler assessments, namely liver cirrhosis.
• Pregnancy Chronic Kidney Disease (CKD) patients on Haemodialysis.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Evaluation of utility of VEXUS score as a marker for acute kidney injury in patients with septic shock.	Will be observed till patient is admitted in intensive care unit.

Secondary Outcome Measures

Name	Time	Method
1.Correlation of VEXUS score with need of renal replacement therapy in sepsis patients.	2.Correlation of VEXUS score with intensive care unit mortality.

Trial Locations

Locations (1)

Max super-speciality Hospital , Saket, New Delhi; 🇮🇳 South, DELHI, India

Max super-speciality Hospital , Saket, New Delhi

🇮🇳South, DELHI, India

Dr Rahul Kumar Sharma

Principal investigator

9968473703

Dr.rahulsharma1992@gmail.com